What question did this study set out to answer?

This research aims to evaluate the efficacy and safety of oral semaglutide 25 mg for treating obesity in individuals with and without type 2 diabetes.

April 25, 2026Open Access

View Full Paper

Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach

RORune Viig OvergaardNovo Nordisk (Denmark)OBOscar BirkhanNovo Nordisk (Denmark)NRNaveen RathorNovo Nordisk (Denmark)

Key Points

This research aims to evaluate the efficacy and safety of oral semaglutide 25 mg for treating obesity in individuals with and without type 2 diabetes.
Compared estimated exposure levels and efficacy of oral semaglutide 25 mg with subcutaneous semaglutide 2.4 mg.
Utilized a model-informed drug development approach.
Efficacy levels of oral semaglutide 25 mg were similar to those of subcutaneous semaglutide 2.4 mg.
Support for using oral semaglutide 25 mg in treating obesity with/without type 2 diabetes.

Abstract

Estimated exposure levels and efficacy observed with oral semaglutide 25 mg were similar to those obtained with subcutaneous semaglutide 2.4 mg, supporting application of oral semaglutide 25 mg to treat individuals with overweight/obesity, with/without T2D.

AI에게 질문

Bookmark

View Full Paper

AI에게 질문

Bookmark

View Full Paper

Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach

Key Points

Abstract

Cite This Study

Also Consider

Also Consider